A-85380 [3-(2(S)-Azetidinylmethoxy) pyridine]: In vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand

Neuropharmacology

Volumn 35, Issue 6, 1996, Pages 725-734

  Sullivan, James P ^a   Donnelly Roberts, Diana ^a   Briggs, Clark A ^a   Anderson, David J ^a   Gopalakrishnan, Murali ^a   Piattoni Kaplan, Marietta ^a   Campbell, Jeffrey E ^a   McKenna, David G ^a   Molinari, Edwardo ^a   Hettinger, Ann Marie ^a   Garvey, David S ^a   Wasicak, James T ^a   Holladay, Mark W ^a   Williams, Michael ^a   Arneric, Stephen P ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ACh acetylcholine; DH E dihydro erythroidine; MLA methyllycaconitine; nAChR nicotinic acetylcholine receptor; BgT bungarotoxin

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; EPIBATIDINE; MECAMYLAMINE; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MALE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

EID: 0030174958     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/0028-3908(96)84644-2     Document Type: Article

References (41)

1. Abreo M. A., Lin N. H., Garvey D. S., Gunn D. E., Hettinger A. M., Wasicak J. T., Pavlik P. A., Martin Y.C., Donnelly-Roberts D., Anderson D. J., Campbell J. E., Piattoni-Kaplan M., Sullivan J. P., Williams M., Arneric S. P., and Holladay M. W. (1996) Novel 3-pyridyl ethers with subnanomolar affinity for central nicotinic acetylcholine receptors. J. Med. Chem. 39: 817-825.
2. Anand R., Peng X., Ballesta J. and Lindstom J. (1993) Pharmacological characterization of α-bungarotoxin-sensitive acetylcholine receptors immunoisolated from chick retina: contrasting properties of α7 and a8 subunit containing subtypes. Molec. Pharmacol. 44: 1046-1050.
3. Arneric S. P., Sullivan J. P., Briggs C. A., Donnelly-Roberts D., Anderson D. J., Raszkiewicz J. L., Hughes M. L., Cadman E. D., Adams P., Garvey D. S., Wasicak J. T. and Williams M. (1994) (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT-418): A novel cholinergic ligand with cognition enhancing and anxiolytic activity I in vitro activity. J. Pharmacol. Exp. Ther. 270: 310-317.
4. Arneric S. P., Sullivan J. P. and Williams M. (1995) Neuronal nicotinic acetylcholine receptors: Novel targets for CNS therapeutics, In: Psychopharmacology: Fourth Generation of Progress (Bloom F.E., Kupfer D.J., Eds) pp. 95-110, Raven Press, New York.
5. Badio B. and Daly J. W. (1994) Epibatidine, a potent analgetic and nicotinic agonist. Molec. Pharmacol. 45: 563-569.
6. Bertrand D., Bertrand S. and Ballivet M. (1992) Pharmacological Properties of the homomeric α7 receptor. Neurosci. Lett. 146: 87-90.
7. Briggs C. A., Hughes M. L., Monteggia L. M., Giordano T., Donnelly-Roberts D. and Arneric S. P. (1995a) Nicotinic cholinergic channel activation by the novel agonist ABT-418 in PC12 cells. Drug Dev. Res. 34: 39-46.
8. Briggs C. A., McKenna D. G. and Piattoni-Kaplan M. (1995b) Human α7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34: 583-590.
9. Changeux J. P., Galzi J. L., Devillers-Thiery A. and Betrand D. (1992) The functional architecture of the acetylcholine nicotinic receptor explored by affinity labeling and site-directed mutagenesis. Quart. Rev. Biophys 25: 395-432.
10. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108.
11. 125I]-α-bungarotoxin. J. Neurosci. 5: 1307-1315.
12. Damaj M. I., Creasy K. R., Grove A. D., Rosecrans J. A. and Martin B. R. (1994) Pharmacological effects of epibatidine optical enantiomers. Brain Res. 664: 34-40.
13. 125I]-α-bungarotoxin receptor subtypes. Molec. Pharmacol. 47: 164-171.
14. Deneris E. S., Connolly J., Rogers S. W. and Duvoism R. (1991) Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol. Sci. 12: 34-40.
15. Elgoyhen A. B., Johnson D., Boulter J., Vetter D. and Heineman S. F. (1994) Alphα-9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 79: 705-715.
16. Enna S. J. and Snyder S. H. (1975) Properties of γ-aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions. Brain Res. 100: 81-87.
17. Flores C. M., Rogers S. W., Pabreza L. A., Wolfe B. and Kellar K. J. (1992) A subtype of nicotinic cholinergic receptor is composed of α4 and β2 subunits and is upregulated by chronic nicotine treatment. Molec. Pharmacol 41: 31-37.
18. Gerzanich V., Anand R. and Lindstrom J. (1994) Homomers of α8 and α7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties. Molec. Pharmacol 45: 212-220.
19. Gopalakrishnan M., Buisson B., Touma E., Giordano T., Campbell J. E., Hu I. C., Bertrand D., Donnelly-Roberts D., Arneric S. P. and Sullivan J. P. (1995) Pharmacological characterization of the human α7 neuronal nicotinic acetylcholine receptor subtype stably expressed in a mammalian cell line. Eur. J. Pharmacol. 290: 237-246.
20. Gopalakrishnan M., Monteggia L. M., Anderson D. J., Piattoni-Kaplan M., Donnelly-Roberts D., Arneric S. P. and Sullivan J. P. (1996) Stable expression, pharmacologic properties and regulation of the human nicotinic acetylcholine α4β2 receptor. J. Pharmacol. Exp. Ther. 276: 289-297.
21. 3H]dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59: 848-856.
22. Levin E. D. (1992) Nicotinic systems and cognitive function. Psychopharmacol. 108: 417-431.
23. Linville D. G., Williams S., Raszkiewicz J. R. and Arneric S. P. (1993) Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow. J. Pharmacol. Exp. Ther. 267: 440-448.
24. 3H] nicotine binding to putative high affinity receptor sites in rat brain. Molec. Pharmacol. 31: 392-400.
25. Listerud M., Brssaard A. B., Devay P., Colman D. R. and Role L. W. (1991) Functional contribution of neuronal AChR subunits revealed by antisense oligonucleotides. Science 254: 1518-1521.
26. Lukas R. J. (1993) Expression of gangliα-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal cell line. J. Pharmacol. Exp. Ther. 265: 294-302.
27. Marin P., Maus M., Desagher S., Glowinski J. and Premont J. (1994) Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuroreport 5: 1977-1980.
28. Marks M. J., Stitzel A., Romm E., Wehner J. M. and Collins A. C. (1986) Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine, and α-bungarotoxin. Molec. Pharmacol. 30: 427-436.
29. McGehee D. S. and Role L. W. (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. A. Rev. Physiol. 57: 521-546.
30. Papke R. (1993) The kinetic properties of neuronal nicotinic receptors: genetic basis of functional diversity. Prog. Neurobiol. 41: 509-531.
31. Peng X., Katz M., Gerzanich V., Anand R. and Lindstrom J. (1994) Human α7 acetylcholine receptor: Cloning of the α7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and function of α7 homomers expressed in Xenopus oocytes. Molec. Pharmacol. 45: 546-554.
32. Qian C., Li T., Shen T. Y., Libertine-Garahan L., Eckman J., Biftu T. and Ip S. (1993) Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol 250: R13-R14.
33. Sargent P. B. (1993) The diversity of neuronal nicotinic acetylcholine receptors. A. Rev. Neurosci. 16: 403-443.
34. Seguela P., Wadiche J., Dineley-Miller K., Dani J. A. and Partick J. W. (1993) Molecular cloning, functional properties and distribution of rat brain α7; a nicotinic cation channel highly permeable to calcium. J. Neurosci. 13: 596-604.
35. Sullivan J. P., Briggs C. A., Donnelly-Roberts D., Brioni J. D., Radek R. J., McKenna D. G., Campbell J. E., Arneric S. P., Decker M. W. and Bannon A. W. (1994a) (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med. Chem. Res. 4: 502-516.
36. Sullivan J. P., Decker M. W., Brioni J. D., Donnelly-Roberts D., Anderson D. J., Bannon A. W., Kang C.-H., Adams P., Piattoni-Kaplan M., Buckley M. J., Gopalakrishnan M., Williams M. and Arneric S. P. (1994b) (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 271: 324-331.
37. Whiting P., Schoepfer R., Lindstrom J. and Priestly T. (1991) Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Molec. Pharmacol 40: 463-472.
38. Williams M. and Robinson J. L. (1984) Binding of the nicotinic cholinergic antagonist dihydro-beta-erythroidine in rat brain tissue. J. Neurosci. 4: 2906-2911.
39. Wong E. T., Holstad S. G., Mennerick S. J., Hong S. E., Zorumski C. F. and Isenberg K. E. (1995) Pharmacological and physiological properties of a putative ganglionic nicotinic receptor, α3β4, expressed in transfected eucaryotic cells. Molec. Brain Res. 28: 101-109.
40. Wonnacott S., Irons J., Rapier C., Thorne B. and Lunt G. G. (1990) Presynaptic modulation of transmitter release by nicotinic receptors, In: Progress in Brain Research (Norberg A., Fuxe K., Holmstedt B. and Sundwall A., Eds) pp. 157-163, Elsevier, Amsterdam. .
41. Wonnacott S., Jackman J. L., Swanson K. L., Rapoport H. and Albuquerque E. X. (1991) Nicotinic pharmacology of anatoxin analogs II. Side chain structure-activity relationships at neuronal nicotinic ligand binding sites. J. Pharmacol Exp. Ther. 259: 387-391.